Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-06-19
2007-06-19
Campell, Bruce R. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S242000, C435S069100, C435S320100, C424S207100, C424S093100
Reexamination Certificate
active
09482682
ABSTRACT:
The present invention relates to methods for gene therapy, especially to adenovirus-based gene therapy, and related cell lines and compositions. In particular, novel nucleic acid constructs and packaging cell lines are disclosed, for use in facilitating the development of high-capacity and targeted vectors. The invention also discloses a variety of high-capacity adenovirus vectors and related compositions and kits including the disclosed cell lines and vectors. Finally, the invention discloses methods of preparing and using the disclosed vectors, cell lines and kits.
REFERENCES:
patent: 4356270 (1982-10-01), Itakura
patent: 4675285 (1987-06-01), Clark et al.
patent: 5149780 (1992-09-01), Plow et al.
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5559099 (1996-09-01), Wickham et al.
patent: 5750396 (1998-05-01), Yang et al.
patent: 5756086 (1998-05-01), McClelland et al.
patent: 5770442 (1998-06-01), Wickham et al.
patent: 5871727 (1999-02-01), Curiel
patent: 5919676 (1999-07-01), Graham et al.
patent: 5994106 (1999-11-01), Kovesdi et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6410011 (2002-06-01), Branellec et al.
patent: 2002/0037851 (2002-03-01), Fleckenstein et al.
patent: 0 892 047 (1999-01-01), None
patent: WO 92/06693 (1992-04-01), None
patent: 9417832 (1994-08-01), None
patent: 9502697 (1995-01-01), None
patent: WO 95/00655 (1995-01-01), None
patent: WO 95/11984 (1995-05-01), None
patent: 9527071 (1995-10-01), None
patent: WO 95/26412 (1995-10-01), None
patent: WO 95/34671 (1995-12-01), None
patent: 9607734 (1996-03-01), None
patent: WO 96/14061 (1996-05-01), None
patent: WO 96/22378 (1996-07-01), None
patent: WO 96/39530 (1996-12-01), None
patent: 9721826 (1997-06-01), None
patent: WO 97/37220 (1997-10-01), None
patent: WO-98/13499 (1998-04-01), None
patent: WO 98/13499 (1998-04-01), None
patent: WO 98/17783 (1998-04-01), None
patent: WO 98/44121 (1998-10-01), None
patent: 0042208 (2000-07-01), None
patent: PCT/EP01/04863 (2001-04-01), None
patent: PCT/EP01/07878 (2001-07-01), None
patent: 0183729 (2001-11-01), None
patent: 0192299 (2001-12-01), None
patent: PCT/US03/02295 (2002-01-01), None
Sequence alignment of SEQ ID No. Sep. 26, 1998. ID No. V32372. Memerow et al. in PCT application 97WO-EPO5251 corresponding to published WO 98/13499.
Stevenson et al. 1997. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiver protein. Journal of Virology. vol. 71. No. 6, pp. 4782-4790.
Guo et al. 1998. Apoptosis induced by adenovirus-mediated wild-type p53 expression in human pancreatic cancer cells. Chinese Journal of Pathology. vol. 27. No. 3, pp. 194-197. Abstract only.
Logan et al. Proc. Natl. Acad. Sci. 1994; 81: 3655-3659.
Sheay et al. Biotechniques. 1993; 15 (5): 856-862.
Kaufman. PNAS. 1985; 82: 689-693.
Hodges et al. Molecular Pharmacology. 1995; 48: 905-918.
Caravokyri et al. Journal of Virology. 1995; 69 (11): 6627-6633.
Zhang et al. “Secondary structure analysis of adenovirus tripartite leader” J. biological Chem. vol. 264 (1989), No. 18, pp. 10679-10684.
Allison, J. et al., “Tissue-Specific and Hormonal Regulation of the Gene for Rat Prostatic Steroid-Binding Protein in Transgenic Mice,”Mol. Cell. Biol. 9:2254-2257, American Society for Microbiology (1989).
Altschul, S.F. et al., Basic Local Alignment Search Tool,J. Mol. Biol. 215:403-410, Academic Press Ltd. (1990).
Amalfitano, A. et al., “Improved Adenovirus Packaging Cell Lines to Support the Growth of Replication-Defective Gene-Delivery Vectors,”Proc. Natl. Acad. Sci. USA 93:3352-3356, The National Academy of Sciences of the USA (Apr. 1996).
Armentano, D. et al., “Characterization of An Adenovirus Gene Transfer Vector Containing an E4 Deletion,”Hum. Gene Ther. 6:1343-1353, Mary Ann Liebert, Inc. (Oct. 1995).
Arnberg, N., et al., “Fiber Genes of Adenoviruses with Tropism for the Eye and the Genital Tract,”Virology 227:239-244, Academic Press, Inc. (Jan. 1997).
Austin, E.A. and Huber, B.E., “A First Step in the Development of Gene Therapy for Colorectal Carcinoma: Cloning, Sequencing, and Expression ofEscherichia coliCytosine Deaminase,”Mol. Pharmacol. 43:380-387, ASPET (1993).
Ausubel, F.M. et al., “Synthesizing RNA,”in Current Protocols in Molecular Biology, Suppl. 8 p. 2.11.7, John Wiley & Sons, Inc. New York (1991).
Berkner, K.L., “Development of Adenovirus Vectors for the Expression of Heterologous Genes,”BioTechniques 6:616-629, Eaton Publishing Co. (1988).
Bett, A.J., et al., “Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors,”J. Virol. 67:5911-5921, American Society for Microbiology (1993).
Bett, A.J., et al., “An Efficient and Flexible System for Construction of Adenovirus Vectors with Insertions or Deletions in Early Regions 1 and 3,”Proc. Natl. Acad. Sci. USA 91:8802-8806, The National Academy of Sciences of the USA (1994).
Birnboim, H.C. and Doly, J., “A rapid alkaline extraction procedure for screening recombinant plasmid DNA,”Nucl. Acids Res. 7:1513-1523, Oxford University Press (1978).
Braun, R.E., et al., “Protamine 3′-Untranslated Sequences Regulate Temporal Translational Control and Subcellular Localization of Growth Hormone in Spermatids of Transgenic Mice,”Genes Dev. 3:793-802, Cold Spring Harbor Laboratory Press (1989).
Brinster, R.L., et al., “Expression of a Microinjected Immunoglobulin Gene in the Spleen of Transgenic Mice,”Nature 306:332-336, Macmillan Magazines Ltd (1983).
Brough, D.E., et al., “A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4,”J. Virol. 70:6497-6501, American Society for Microbiology (Sep. 1996).
Brown, E.L., et al., “Chemical Synthesis and Cloning of a Tyrosine tRNA Gene,”Meth. Enzymol. 68:109-151, Academic Press, Inc. (1979).
Bucchini, D., et al., “Pancreatic Expression of Human Insulin Gene in Transgenic Mice,”Proc. Natl. Acad. Sci. USA 83:2511-2515, The National Academy of Sciences of the USA (1986).
Cannon, M.J., et al., “Epstein-Barr Virus Induces Aggressive Lymphoproliferative Disorders of Human B Cell Origin in SCID/hu Chimeric Mice,”J. Clin. Invest. 85:1333-1337, The Rockefeller University Press (1990).
Carillo, H., and Lipton, D., “The Multiple Sequence Alignment Problem in Biology,”SIAM J. Applied Math 48:1073, Society for Industrial and Applied Mathematics (1988).
Chee-Sheung, C.C. et al., “Characterization of a Temperature-Sensitive Fiber Mutant of Type 5 Adenovirus and Effect of the Mutation on Virion Assembly,”J. Virol. 42:932-950, American Society for Microbiology (1982).
Choi, T., et al., “A Generic Intron Increases Gene Expression in Transgenic Mice,”Mol. Cell Biol. 11:3070-3074, American Society for Microbiology (1991).
Chroboczek, J., et al., “The Sequence of Adenovirus Fiber: Similarities and Differences Between Serotypes 2 and 5,”Virology 161:549-554, Academic Press, Inc. (1987).
Chroboczek, J., et al., “The Sequence of the Genome of Adenovirus Type 5 and Its Comparison with the Genome of Adenovirus Type 2,”Virology 185:280-285, Academic Press, Inc. (1992).
Chroboczek,J., et al., GenBank Accession No. M73260, (Apr. 8, 1996).
Crenshaw, E.B., 3rd, et al., “Cell-Specific Expression of the Prolactin Gene in Transgenic Mice is Controlled by Synergistic Interactions Between Promoter and Enhancer Elements,”Genes Dev. 3:959-972, Cold Spring Laboratory Press (1989).
Crystal, R.G., et al., “Administration of an Adenovirus Containing the Human CFTR cDNA to the Respiratory Tract of Individuals with Cystic Fibrosis,”Nature Genet. 8:42-51, Macmillan Magazines Ltd (1994).
Danciger, E., et al., “Olfactory Marker Protein Gene: Its Structure and Olfactory Neuron-Specific Expression in Transgenic Mice,”Proc. Natl. Acad. Sci. USA 86:8565-8569, The National Academy
Nemerow Glen R.
Von Seggern Daniel J.
Campell Bruce R.
DLA Piper (US) LLP
Peng Bo
The Scripps Research Institute
LandOfFree
Adenovirus vectors, packaging cell lines, compositions, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenovirus vectors, packaging cell lines, compositions, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenovirus vectors, packaging cell lines, compositions, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3832580